Ilaria D'Agostino, Githa Elizabeth Mathew, Paola Angelini, Roberto Venanzoni, Giancarlo Angeles Flores, Andrea Angeli, Simone Carradori, Beatrice Marinacci, Luigi Menghini, Mohamed A Abdelgawad, Mohammed M Ghoneim, Bijo Mathew, Claudiu T Supuran
The enormous burden of the COVID-19 pandemic in economic and healthcare terms has cast a shadow on the serious threat of antimicrobial resistance, increasing the inappropriate use of antibiotics and shifting the focus of drug discovery programmes from antibacterial and antifungal fields. Thus, there is a pressing need for new antimicrobials involving innovative modes of action (MoAs) to avoid cross-resistance rise. Thiosemicarbazones (TSCs) stand out due to their easy preparation and polypharmacological application, also in infectious diseases...
December 2022: Journal of Enzyme Inhibition and Medicinal Chemistry